ClinicalTrials.gg
CompletedNCT05450198Updated Jun 5, 2025Results posted

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

A Phase 1 interventional study of MK-6194 and Placebo in Dermatitis, Atopic, sponsored by Merck Sharp & Dohme LLC. Completed at 19 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
302nd of 544
72 · median 96
Started
2022
with 44 others
Phase 1
82 of 639
10 open now
Registered
469th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 302nd largest by enrollment of the 544 interventional ones that give a count, is one of 45 that started in 2022, is one of 82 in phase 1, and was the 469th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Clinical diagnosis of atopic dermatitis for at least 6 months prior to the Screening visit.
  • Atopic dermatitis is of at least moderate severity.
  • History of inadequate response to a stable (≥1 month) regimen of medium to high potency topical or calcineurin inhibitors as treatment for atopic dermatitis within 6 months before the screening visit.
  • (BMI) ≥18 and ≤38 kg/m2 at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Concurrent significant skin disease other than atopic dermatitis (such as psoriasis) or a concurrent disease.
  • Significant organ dysfunction that is unstable or inadequately treated within 6 months prior to Screening.
  • History of cancer (), with the exceptions: of adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or; other malignancies that have been successfully treated with appropriate follow up.
  • History of myocardial infarction, congestive heart failure, uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months of Screening.
  • History of organ or tissue allograft.
  • History of symptomatic herpes zoster within 16 weeks of randomization, or any history of disseminated herpes simplex, disseminated herpes zoster, ophthalmic zoster, or central nervous system (CNS) zoster.
  • Major surgery within 3 months prior to the screening visit or has a major surgery planned during the study.
  • Received a live or attenuated virus vaccine within 4 weeks prior to the Screening visit or intends to receive live or attenuated virus vaccination during the course of the study and for 12 weeks after the last dose of study drug.
  • Currently receiving any chronic systemic (oral or intravenous) anti-infective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Dose Escalation Panel A

    Participants are randomized to low dose MK-6194 or placebo, administered every 2 weeks (q2w).

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Dose Escalation Panel B

    Participants are randomized to medium dose MK-6194 or placebo administered q2w.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Dose Escalation Panel C

    Participants are randomized to high dose MK-6194 or placebo administered q2w.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Expansion Panel D

    Participants are randomized to medium dose MK-6194 or placebo administered q2w.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Expansion Panel E

    Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo administered q2w.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Expansion Dose F

    Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo q2w.

    Biological: MK-6194 · Biological: Placebo

Interventions

  • BiologicalMK-6194

    MK-6194 administered subcutaneously (SC)

  • BiologicalPlacebo

    Placebo comparator to MK-6194 administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.

    Time frame: Up to approximately 169 days

  2. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.

    Time frame: Up to approximately 85 days

Secondary outcomes

  1. Area Under the Curve (AUC) From Days 1-15 (AUC1-15) of MK-6194

    Blood samples were collected at pre-specified time points to determine the AUC1-15 of MK-6194 in plasma.

    Time frame: Day 1 (Predose and 12 hours postdose), Day 8, and Day 15

  2. AUC From Days 29-43 (AUC29-43) of MK-6194

    Blood samples were collected at pre-specified time points to determine the AUC29-43 of MK-6194 in plasma.

    Time frame: Day 29 (Predose and 12 hours postdose), Day 36, and Day 43

  3. Peak Serum Concentration (Cmax) of MK-6194 (Day 1 to 29)

    Blood samples were collected at pre-specified time points to determine the Cmax of MK-6194 in plasma.

    Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, and Day 29 (Predose and 12 hours postdose)

  4. Minimum Serum Concentration (Ctrough) of MK-6194 (Day 1 to 29)

    Blood samples were collected at pre-specified time points to determine the Ctrough of MK-6194 in plasma.

    Time frame: Predose on Days 15 and 29

  5. Time to Peak Serum Concentration (Tmax) of MK-6194 (Day 1 to 29)

    Blood samples were collected at pre-specified time points to determine the Tmax of MK-6194 in plasma.

    Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, and Day 29 (Predose and 12 hours postdose)

  6. Geometric Mean Accumulation Ratio of AUC of MK-6194

    Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of AUC of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.

    Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, Day 29 (Predose and 12 hours postdose), Day 36, and Day 43

  7. Geometric Mean Accumulation Ratio of Cmax of MK-6194

    Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of Cmax of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.

    Time frame: Day 1 (Predose and 12 hours postdose), Day 8, Day 15, Day 29 (Predose and 12 hours postdose), Day 36, and Day 43

  8. Fold Change From Baseline in Peak Regulatory T Cells (Tregs)

    Blood samples were collected to determine the fold change from baseline (FCB) in peak Tregs. The peak Treg FCB was evaluated after the last dose of MK-6194 on Day 85 using natural-log transformed values with a linear model containing fixed effects.

    Time frame: Baseline and Day 85

07

Results

Posted Jun 5, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Started1863612
Completed1653211
Not completed2141
Withdrew: Withdrawal by subject1120
Withdrew: Lost to follow-up1021

Outcome measures

SecondaryArea Under the Curve (AUC) From Days 1-15 (AUC1-15) of MK-6194

Blood samples were collected at pre-specified time points to determine the AUC1-15 of MK-6194 in plasma.

Time frame:
Day 1 (Predose and 12 hours postdose), Day 8, and Day 15
Reported as:
Geometric least squares mean · day*ng/mL
Area Under the Curve (AUC) From Days 1-15 (AUC1-15) of MK-6194
day*ng/mLPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Area Under the Curve (AUC) From Days 1-15 (AUC1-15) of MK-6194—32.3 (13.9 to 75.1)59.6 (43.8 to 81.1)—
SecondaryAUC From Days 29-43 (AUC29-43) of MK-6194

Blood samples were collected at pre-specified time points to determine the AUC29-43 of MK-6194 in plasma.

Time frame:
Day 29 (Predose and 12 hours postdose), Day 36, and Day 43
Reported as:
Geometric least squares mean · day*ng/mL
AUC From Days 29-43 (AUC29-43) of MK-6194
day*ng/mLPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
AUC From Days 29-43 (AUC29-43) of MK-6194—10.9 (4.13 to 28.7)56.7 (41.7 to 77.0)86.7 (47.0 to 160)
SecondaryPeak Serum Concentration (Cmax) of MK-6194 (Day 1 to 29)

Blood samples were collected at pre-specified time points to determine the Cmax of MK-6194 in plasma.

Time frame:
Day 1 (Predose and 12 hours postdose), Day 8, Day 15, and Day 29 (Predose and 12 hours postdose)
Reported as:
Geometric least squares mean · ng/mL
Peak Serum Concentration (Cmax) of MK-6194 (Day 1 to 29)
ng/mLPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Peak Serum Concentration (Cmax) of MK-6194 (Day 1 to 29)—13.2 (6.34 to 27.3)21.7 (16.8 to 27.9)20.0 (12.9 to 31.1)
SecondaryMinimum Serum Concentration (Ctrough) of MK-6194 (Day 1 to 29)

Blood samples were collected at pre-specified time points to determine the Ctrough of MK-6194 in plasma.

Time frame:
Predose on Days 15 and 29
Reported as:
Geometric least squares mean · ng/mL
Minimum Serum Concentration (Ctrough) of MK-6194 (Day 1 to 29)
ng/mLPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Minimum Serum Concentration (Ctrough) of MK-6194 (Day 1 to 29)——0.210 (0.0141 to 3.13)—
SecondaryTime to Peak Serum Concentration (Tmax) of MK-6194 (Day 1 to 29)

Blood samples were collected at pre-specified time points to determine the Tmax of MK-6194 in plasma.

Time frame:
Day 1 (Predose and 12 hours postdose), Day 8, Day 15, and Day 29 (Predose and 12 hours postdose)
Reported as:
Geometric least squares mean · day
Time to Peak Serum Concentration (Tmax) of MK-6194 (Day 1 to 29)
dayPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Time to Peak Serum Concentration (Tmax) of MK-6194 (Day 1 to 29)—0.49 (0.48 to 0.49)0.49 (0.48 to 0.51)0.49 (0.42 to 0.50)
SecondaryGeometric Mean Accumulation Ratio of AUC of MK-6194

Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of AUC of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.

Time frame:
Day 1 (Predose and 12 hours postdose), Day 8, Day 15, Day 29 (Predose and 12 hours postdose), Day 36, and Day 43
Reported as:
Geometric least squares mean · Ratio
Geometric Mean Accumulation Ratio of AUC of MK-6194
RatioPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Geometric Mean Accumulation Ratio of AUC of MK-6194—0.35 (0.13 to 0.96)0.98 (0.70 to 1.38)—
SecondaryGeometric Mean Accumulation Ratio of Cmax of MK-6194

Blood samples were collected at pre-specified time points to determine the geometric mean accumulation ratio of Cmax of MK-6194. The accumulation ratio is defined as Day 29-43/ Day 1-15.

Time frame:
Day 1 (Predose and 12 hours postdose), Day 8, Day 15, Day 29 (Predose and 12 hours postdose), Day 36, and Day 43
Reported as:
Geometric least squares mean · Ratio
Geometric Mean Accumulation Ratio of Cmax of MK-6194
RatioPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Geometric Mean Accumulation Ratio of Cmax of MK-6194—0.84 (0.41 to 1.72)0.98 (0.79 to 1.20)1.35 (0.94 to 1.94)
SecondaryFold Change From Baseline in Peak Regulatory T Cells (Tregs)

Blood samples were collected to determine the fold change from baseline (FCB) in peak Tregs. The peak Treg FCB was evaluated after the last dose of MK-6194 on Day 85 using natural-log transformed values with a linear model containing fixed effects.

Time frame:
Baseline and Day 85
Reported as:
Geometric least squares mean · Fold change from baseline
Fold Change From Baseline in Peak Regulatory T Cells (Tregs)
Fold change from baselinePlaceboMK-6194 Low Dose of (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)
Fold Change From Baseline in Peak Regulatory T Cells (Tregs)1.15 (0.83 to 1.59)1.86 (0.95 to 3.66)1.69 (1.27 to 2.24)1.58 (1.05 to 2.38)
PrimaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.

Time frame:
Up to approximately 169 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
ParticipantsPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)MK-6194 Total
Number of Participants Who Experience One or More Adverse Events (AEs)13630945
PrimaryNumber of Participants Who Discontinue Study Intervention Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.

Time frame:
Up to approximately 85 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Intervention Due to an AE
ParticipantsPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)MK-6194 Total
Number of Participants Who Discontinue Study Intervention Due to an AE01203

Adverse events

Collected over Up to approximately 169 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)0/18 (0%)13/18 (72.2%)
MK-6194 Low Dose (Panel A)0/6 (0%)0/6 (0%)6/6 (100%)
MK-6194 High Dose (Panels B-E)0/36 (0%)2/36 (5.6%)30/36 (83.3%)
MK-6194 High Dose (Panel F)0/12 (0%)0/12 (0%)9/12 (75%)
MK-6194 Total0/54 (0%)2/54 (3.7%)45/54 (83.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panels B-E)MK-6194 High Dose (Panel F)MK-6194 Total
Inguinal herniaGastrointestinal disorders0/180/61/360/121/54
MalaiseGeneral disorders0/180/61/360/121/54
Most frequent other events
Showing 10 of 92
Most frequent other events
EventPlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panels B-E)MK-6194 High Dose (Panel F)MK-6194 Total
Injection site erythemaGeneral disorders0/186/625/366/1237/54
Injection site indurationGeneral disorders0/183/68/360/1211/54
Injection site painGeneral disorders0/183/66/362/1211/54
NasopharyngitisInfections and infestations2/180/63/365/128/54
NauseaGastrointestinal disorders0/182/60/360/122/54
PruritusSkin and subcutaneous tissue disorders0/182/60/360/122/54
EosinophiliaBlood and lymphatic system disorders0/181/67/363/1211/54
Injection site swellingGeneral disorders0/181/67/363/1211/54
HeadacheNervous system disorders4/181/64/360/125/54
DiarrhoeaGastrointestinal disorders1/180/60/362/122/54

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)Total
Mean37.2 ± 11.046.5 ± 11.342.8 ± 16.842.0 ± 16.541.6 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)Total
Female5218530
Male13418742
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)Total
Hispanic or Latino306110
Not Hispanic or Latino156301162
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMK-6194 Low Dose (Panel A)MK-6194 High Dose (Panel B-E)MK-6194 High Dose (Panel F)Total
American Indian or Alaska Native10001
Asian00101
Native Hawaiian or Other Pacific Islander10001
Black or African American20327
White146311061
More than one race00101
Unknown or Not Reported00000
08

Study locations

19 sites
  • Arkansas Research Trials-Clinical Trials ( Site 0002)
    North Little Rock, Arkansas 72117, United States
  • Global Health Research Center, Inc. ( Site 0005)
    Miami Lakes, Florida 33016, United States
  • Miami Dermatology and Laser Research ( Site 0025)
    Miami, Florida 33173, United States
  • Genesis Clinical Research, LLC ( Site 0004)
    Tampa, Florida 33603, United States
  • ForCare Clinical Research ( Site 0003)
    Tampa, Florida 33613, United States
  • Advanced Medical Research, PC. ( Site 0027)
    Sandy Springs, Georgia 30328, United States
  • AXIS Clinicals ( Site 0029)
    Dilworth, Minnesota 56529, United States
  • Remington Davis Clinical Research ( Site 0021)
    Columbus, Ohio 43215, United States
  • Paddington Testing Company ( Site 0010)
    Philadelphia, Pennsylvania 19103, United States
  • North Texas Center for Clinical Research ( Site 0028)
    Frisco, Texas 75034, United States
  • Progressive Clinical Research ( Site 0022)
    San Antonio, Texas 78213, United States
  • Complete Dermatology ( Site 0023)
    Sugar Land, Texas 77478, United States
  • Premier Clinical Research ( Site 0026)
    Spokane, Washington 99202, United States
  • Anima ( Site 0013)
    Alken, Limburg 3570, Belgium
  • ARENSIA Exploratory Medicine - Sofia ( Site 0018)
    Sofia, Sofia (stolitsa) 1618, Bulgaria
  • Innovaderm Research Inc. ( Site 0019)
    Montréal, Quebec H2X 2V1, Canada
  • ARENSIA Exploratory Medicine-SC ARENSIA Exploratory Medicine SRL with Monza Medical Center ( Site 00
    Bucharest, Bucuresti 11658, Romania
  • ARENSIA Exploratory Medicine-Country Emergency Hospital- Arensia,Cluj-Napoca ( Site 0017)
    Cluj-Napoca, Cluj 400006, Romania
  • Hospital Germans Trias i Pujol-CCEE Dermatologia ( Site 0012)
    Badalona, Barcelona 08916, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in May 2024, 21 months.

Results were first posted in Jun 2025, 1 year after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 21 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 8, 2022
StartActual
Aug 8, 2022
Primary completionActual
May 22, 2024
CompletionActual
May 22, 2024
Results first posted
Jun 5, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05450198
Responsible party
Sponsor
First posted
Jul 8, 2022
Start date
Aug 8, 2022
Primary completion
May 22, 2024
Completion
May 22, 2024
Results posted
Jun 5, 2025
Last update
Jun 5, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6194

Start the discussion